IvWatch

Executive Summary

IvWatch is a US-based medical device and digital health company dedicated to improving patient safety through continuous monitoring for intravenous (IV) infiltration and extravasation events. Founded in 2010 and headquartered in Hampton, Virginia, the company has developed a proprietary, non-invasive sensor system that attaches to an IV site and wirelessly transmits real-time data to nursing stations. By detecting tissue changes indicative of fluid leakage earlier than standard clinical assessments, IvWatch enables timely intervention, reducing complications such as tissue damage, nerve injury, and extended hospital stays. The system is designed to complement existing nursing protocols, offering a scalable solution for hospitals aiming to enhance patient outcomes and reduce liability risks associated with IV therapy complications. The market for IV infiltration detection devices is growing, driven by increasing awareness of patient safety, value-based care reimbursement models, and the high costs of adverse events. IvWatch competes in a niche but critical segment, with limited direct competition from alternative monitoring technologies or manual checklists. The company's potential for growth lies in expanding adoption across major hospital systems, securing FDA clearances for additional patient populations (e.g., pediatrics, oncology), and leveraging data analytics to improve clinical workflows. With a strong focus on evidence generation and partnerships, IvWatch is well-positioned to capture a meaningful share of the hospital patient safety market, provided it can navigate procurement cycles and demonstrate clear return on investment.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for pediatric use65% success
• Q2 2026Published clinical study demonstrating reduced infiltration rates in a multi-center trial55% success
• Q3 2026Strategic partnership or contract with a major US hospital network60% success